Safety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settings
The review used 61 literature sources to discuss 13 publications devoted to safety of treatment of HIV-associated drug-resistant tuberculosis using basic and new regimens of chemotherapy. According to the literature, no additive toxic effects were detected during treatment with anti-tuberculosis and...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
New Terra Publishing House
2022-12-01
|
| Series: | Туберкулез и болезни лёгких |
| Subjects: | |
| Online Access: | https://www.tibl-journal.com/jour/article/view/1693 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850283847260831744 |
|---|---|
| author | A. V. Kukurika E. I. Veselova L. E. Parolina O. V. Lovacheva |
| author_facet | A. V. Kukurika E. I. Veselova L. E. Parolina O. V. Lovacheva |
| author_sort | A. V. Kukurika |
| collection | DOAJ |
| description | The review used 61 literature sources to discuss 13 publications devoted to safety of treatment of HIV-associated drug-resistant tuberculosis using basic and new regimens of chemotherapy. According to the literature, no additive toxic effects were detected during treatment with anti-tuberculosis and antiretroviral drugs. According to the literature data, no additive toxic effect was found during treatment with anti-tuberculosis and antiretroviral drugs. In conditions of high prevalence of HIV, the pharmacovigilance of drug interactions in combination therapy is particularly relevant since HIV can indirectly increase the number of ADRs not only due to cross-toxicity but also severe immunosuppression, development of immune system recovery syndrome, opportunistic infections, a characteristic intoxication syndrome, a low index body weight and individual characteristics of patients in this category. |
| format | Article |
| id | doaj-art-bcd7ea4f83d648b29700ac5bbd76a89e |
| institution | OA Journals |
| issn | 2075-1230 2542-1506 |
| language | Russian |
| publishDate | 2022-12-01 |
| publisher | New Terra Publishing House |
| record_format | Article |
| series | Туберкулез и болезни лёгких |
| spelling | doaj-art-bcd7ea4f83d648b29700ac5bbd76a89e2025-08-20T01:47:41ZrusNew Terra Publishing HouseТуберкулез и болезни лёгких2075-12302542-15062022-12-0110011566510.21292/2075-1230-2022-100-11-56-651688Safety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settingsA. V. Kukurika0E. I. Veselova1L. E. Parolina2O. V. Lovacheva3National Medical Research Center of Phthisiopulmonology and Infectious DiseasesNational Medical Research Center of Phthisiopulmonology and Infectious DiseasesNational Medical Research Center of Phthisiopulmonology and Infectious Diseases; Pirogov Russian National Research Medical UniversityNational Medical Research Center of Phthisiopulmonology and Infectious Diseases; Russian Medical Academy of On-going Professional EducationThe review used 61 literature sources to discuss 13 publications devoted to safety of treatment of HIV-associated drug-resistant tuberculosis using basic and new regimens of chemotherapy. According to the literature, no additive toxic effects were detected during treatment with anti-tuberculosis and antiretroviral drugs. According to the literature data, no additive toxic effect was found during treatment with anti-tuberculosis and antiretroviral drugs. In conditions of high prevalence of HIV, the pharmacovigilance of drug interactions in combination therapy is particularly relevant since HIV can indirectly increase the number of ADRs not only due to cross-toxicity but also severe immunosuppression, development of immune system recovery syndrome, opportunistic infections, a characteristic intoxication syndrome, a low index body weight and individual characteristics of patients in this category.https://www.tibl-journal.com/jour/article/view/1693mdr/xdr-tbhivsafetyadverse eventsanti-tb drugsantiretroviral therapytreatment regimens |
| spellingShingle | A. V. Kukurika E. I. Veselova L. E. Parolina O. V. Lovacheva Safety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settings Туберкулез и болезни лёгких mdr/xdr-tb hiv safety adverse events anti-tb drugs antiretroviral therapy treatment regimens |
| title | Safety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settings |
| title_full | Safety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settings |
| title_fullStr | Safety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settings |
| title_full_unstemmed | Safety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settings |
| title_short | Safety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settings |
| title_sort | safety of chemotherapy of mdr xdr tb patients in high hiv prevalence settings |
| topic | mdr/xdr-tb hiv safety adverse events anti-tb drugs antiretroviral therapy treatment regimens |
| url | https://www.tibl-journal.com/jour/article/view/1693 |
| work_keys_str_mv | AT avkukurika safetyofchemotherapyofmdrxdrtbpatientsinhighhivprevalencesettings AT eiveselova safetyofchemotherapyofmdrxdrtbpatientsinhighhivprevalencesettings AT leparolina safetyofchemotherapyofmdrxdrtbpatientsinhighhivprevalencesettings AT ovlovacheva safetyofchemotherapyofmdrxdrtbpatientsinhighhivprevalencesettings |